MicroBiome Therapeutics (formerly NuMe Health) announced positive top-line results from the company’s clinical trial of their lead product, a microbiome modulator being developed for type 2 diabetes and prediabetes. The modulator is designed to improve glucose tolerance in diabetic patients by shifting the gastrointestinal (GI) microbiome.
February 18, 2014 – Read more at The Pharma Letter
New Orleans BioInnovation Center granted funds to pilot diversity program in Life-Sciences Entrepreneurship Investment from JPMorgan Chase will help launch program in partnership with Xavier University of Louisiana NEW ORLEANS…
New technology revolutionizes DNA testing of sexual assault samples InnoGenomics SpermX™ delivers reliable results to solve sexual assault crimes NEW ORLEANS (March 28, 2023) – Addressing a long-term shortcoming in…
Local Biotech Company is Improving Clinical Care for Animals PetVet Dx celebrated recent expansion and future plans at a community event Friday NEW ORLEANS (March 31, 2023) Local biotech company…